BeyondSpring Inc. | TalkMarkets

Latest Posts

Week In Review: Signs Of Life After Coronavirus -- China Biopharma Scores $721 Million In Deals

Article By: ChinaBio® Today

Saturday, April 4, 2020 4:57 PM EDT

Shanghai ZhenGe Biotech, a China CDMO, completed a $51 million Series A financing round led by Shanghai-based healthcare investment firm Lyfe Capita. The company will use the proceeds for additional hires and to expand its Shanghai R&D center

In this article: HCM, BYSI, SNCA

Read

Week In Review: China Life Science Deals Total $550 Million

Article By: ChinaBio® Today

Saturday, December 9, 2017 4:13 PM EDT

Pfizer (NYSE: PFE) signed a $226 million agreement for China/Asian rights to Cresemba® (isavuconazole), an antifungal drug and Everest Medicines announced a $224 million partnership with San Diego's Arena Pharma.

In this article: JNJ, GNBT, BYSI, BMY, ARNA, BABA, PFE

Read

Week In Review: China Resources Pharma Files For $369 Million China Life Science Investment Fund

Article By: ChinaBio® Today

Saturday, October 28, 2017 5:31 PM EDT

China Resources Pharmaceutical (HK: 3320) filed with the Hong Kong exchange to raise $368.5 million in an investment fund. The fund will be run by its subsidiary, CR Pharm (Shantou). It will make equity investments in China pharma companies.

In this article: HCM, BYSI

Read

Week In Review: Beigene Sets Record With $1.4 Billion Celgene Deal

Article By: ChinaBio® Today

Saturday, July 8, 2017 2:35 PM EDT

BeiGene of Beijing has entered a "transformational" collaboration with Celgene which involves BeiGene's clinical-stage PD-1 immuno-oncology drug, has a total value of almost $1.4 billion.

In this article: CELG, QGEN, BGNE, BYSI, ATNX

Read